Quantitative Models of Phage-Antibiotic Combination Therapy

Author:

Rodriguez-Gonzalez Rogelio A.12,Leung Chung Yin23,Chan Benjamin K.4,Turner Paul E.45,Weitz Joshua S.23ORCID

Affiliation:

1. Interdisciplinary Graduate Program in Quantitative Biosciences, Georgia Institute of Technology, Atlanta, Georgia, USA

2. School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA

3. School of Physics, Georgia Institute of Technology, Atlanta, Georgia, USA

4. Department of Ecology and Evolutionary Biology, Yale University, New Haven, Connecticut, USA

5. Program in Microbiology, Yale School of Medicine, New Haven, Connecticut, USA

Abstract

This work develops and analyzes a novel model of phage-antibiotic combination therapy, specifically adapted to an in vivo context. The objective is to explore the underlying basis for clinical application of combination therapy utilizing bacteriophage that target antibiotic efflux pumps in Pseudomonas aeruginosa . In doing so, the paper addresses three key questions. How robust is combination therapy to variation in the resistance profiles of pathogens? What is the role of immune responses in shaping therapeutic outcomes? What levels of phage and antibiotics are necessary for curative success? As we show, combination therapy outperforms either phage or antibiotic alone, and therapeutic effectiveness is enhanced given interaction with innate immune responses. Notably, therapeutic success can be achieved even at subinhibitory concentrations of antibiotic. These in silico findings provide further support to the nascent application of combination therapy to treat MDR bacterial infections, while highlighting the role of system-level feedbacks in shaping therapeutic outcomes.

Funder

National Science Foundation

Cystic Fibrosis Foundation

DOD | United States Army | RDECOM | Army Research Office

Publisher

American Society for Microbiology

Subject

Computer Science Applications,Genetics,Molecular Biology,Modeling and Simulation,Ecology, Evolution, Behavior and Systematics,Biochemistry,Physiology,Microbiology

Reference44 articles.

1. World Health Organization. 2017. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Technical report WHO/EMP/IAU/2017.12. World Health Organization, Geneva, Switzerland.

2. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Technical report. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA.

3. European Centre for Disease Prevention and Control and European Medicines Agency. 2009. The bacterial challenge: time to react. Technical report EMEA/576176/2009. European Centre for Disease Prevention and Control/European Medicines Agency, Solna, Sweden.

4. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence

5. Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3